Loading…
Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.
Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.
Earns from US generic drugs, sold mainly to wholesalers and pharmacy chains at competitive prices, and from branded medicines that Indian doctors prescribe. The US is its largest single market. The Patel family, with Chairman Pankaj Patel, is the promoter and controlling shareholder.
In one line: India's smaller Teva Pharmaceutical.
Moat: narrow (regulatory licence, scale, process know-how). FDA-approved manufacturing facilities and a broad generics pipeline built over decades of regulatory filings.
Headquarters: Ahmedabad, India · Founded: 1952 · Employees: 36,827
Size Zydus Lifesciences (ZYDUSLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $12.7B, the 88th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,198 on 6 Nov 2026.
Performance Over six months the shares gained 27.4%, against +4.5% for the median peer and 0.0% for the India market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 24.0% over the last twelve months (peer median +14.5%); the operating margin is 17.0% (peer median 20.6%).
Valuation It trades at 29.8× forward earnings against a peer median of 23.5× (9th most expensive of 18).
Capital Return on invested capital runs 1.9 points below its cost of capital (11.2% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹304B | ₹270B | ₹229B | ₹193B | ₹171B |
| Revenue growth | — | +18% | +19% | +13% | — |
| Gross profit | ₹150B | ₹134B | ₹114B | ₹86.3B | ₹68.0B |
| EBITDA | ₹71.9B | ₹71.9B | ₹65.8B | ₹50.7B | ₹34.1B |
| Net income | ₹41.8B | ₹50.4B | ₹45.3B | ₹38.6B | ₹19.6B |
| Free cash flow | n/a | -₹4.80B | ₹51.8B | ₹23.8B | ₹16.1B |
| Capital expenditure | n/a | ₹33.9B | ₹16.9B | ₹9.07B | ₹10.3B |
| Total debt | ₹140B | ₹125B | ₹32.2B | ₹8.04B | ₹11.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE.NS | $12.7B | +27% | +24% | 17% | 29.8× | n/a |
| Torrent Pharmaceuticals TORNTPHARM.NS | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $47.3B | +1% | +12% | 23% | 35.4× | 28.4% |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZYDUSLIFE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | +8.1% | 7th lowest of 21 |
| 6-month return | +27.4% | +4.5% | 8th highest of 21 |
| Distance from 52-week high | -5.4% | -10.4% | 7th highest of 21 |
| Revenue growth (TTM) | +24.0% | +14.5% | 8th highest of 20 |
| Operating margin | 17.0% | 20.6% | 9th lowest of 20 |
| Forward P/E | 29.8× | 23.5× | 9th most expensive of 18 |
| ROIC minus cost of capital | -1.9 pp | +1.6 pp | 6th lowest of 20 |
| EV / EBITDA | 18.2× | 15.9× | 6th most expensive of 13 |
| Net debt / EBITDA | 1.2× | -0.1× | 4th most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Pharmaron Beijing 3759.HK | Hong Kong | $11.3B | +45% | +24% | 14% | 22.9× | n/a | n/a |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| PharmaEssentia 6446.TW | Taiwan | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% | +94.8% |
| Ascendis Pharma A/S ASND | United States | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% | +152.4% |
| Orion ORNAV.HE | Finland | $16.1B | +51% | +34% | 38% | 23.5× | -6.3% | +11.7% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |